传奇生物宣布将在EHA 2026上作突破性口头报告,展示LB2501在非霍奇金淋巴瘤中的初步1期体内CAR-T数据

美股速递
Jun 02

传奇生物公司宣布,其针对非霍奇金淋巴瘤的候选药物LB2501的初步1期体内CAR-T研究数据,将在2026年欧洲血液学协会大会上以突破性口头报告的形式进行展示。这一进展标志着公司在细胞治疗领域,特别是针对血液系统恶性肿瘤的体内CAR-T疗法开发方面,迈出了重要一步。此次报告将重点呈现该疗法的早期安全性、可行性及初步疗效信号,为后续临床开发提供关键依据。非霍奇金淋巴瘤作为一种常见的血液癌症,存在显著的未满足临床需求,而体内CAR-T技术旨在简化治疗流程,有望提升疗法的可及性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10